p21^Cip1 Confers resistance to imatinib in human chronic myeloid leukemia cells

详细信息    查看全文

• 作者：Nuria Ferr ; iz ; Juan M. Caraballo ; Marta Albajar ; M. Teresa Gomez-Casares ; Carmen E. Lopez-Jorge ; Rosa Blanco ; M. Dolores Delgado ; Javier Leon
• 关键词：p21 ; Imatinib ; Chronic myeloid leukemia ; Apoptosis
• 刊名：Cancer Letters
• 出版年：2010
• 出版时间：1 June 2010
• 年：2010
• 卷：292
• 期：1
• 页码：133-139
• 全文大小：860 K

文摘

Imatinib is a Bcr-Abl inhibitor used as first-line therapy of chronic myeloid leukemia (CML). p21^Cip1, initially described as a cell cycle inhibitor, also protects from apoptosis in some models. We describe that imatinib down-regulates p21^Cip1 expression in CML cells. Using K562 cells with inducible p21 expression and transient transfections we found that p21 confers partial resistance to imatinib-induced apoptosis. This protection is not related to the G2-arrest provoked by p21, a decrease in the imatinib activity against Bcr-Abl or a cytoplasmic localization of p21. The results suggest an involvement of p21^Cip1 in the response to imatinib in CML.